FDA has placed a clinical hold on the dual COVID-19 and influenza vaccine trial from protein-based vaccine manufacturer Novavax, the company announced Wednesday (Oct. 16), due to a report of a serious adverse event of motor neuropathy. While not definitely linked to the vaccine, the report comes at a time of falling trust in COVID immunization. The adverse event occurred in one trial participant outside the United States in Novavax’s Phase 2 trial. The participant received the vaccine in January...